Case 3: Pancreatitis Risk with Incretin Therapies: Is It Real? Case: Pancreatitis Risk with Incretin Therapy

Size: px
Start display at page:

Download "Case 3: Pancreatitis Risk with Incretin Therapies: Is It Real? Case: Pancreatitis Risk with Incretin Therapy"

Transcription

1 Case 3: Pancreatitis Risk with Incretin Therapies: Is It Real? Case: Pancreatitis Risk with Incretin Therapy 43-year-old obese woman Long-standing type 2 diabetes Currently treated with metformin 1000 mg BID and glyburide 10 mg BID History of dyslipidemia treated with atorvastatin 40 mg/day and fenofibrate 120 mg/day History of silent solitary gall stone discovered incidentally by ultrasound for fatty liver Rarely drinks alcohol A1C 7.8% Case: Pancreatitis Risk with Incretin Therapy No history of pancreatitis Heard from a friend, who also has diabetes, that exenatide is a drug that may help her in controlling her diabetes and may also help her to lose weight She is asking for your opinion about adding exenatide to her current medications but she is concerned about the pancreatitis risk 1

2 Conclusions: This study confirms prior findings that the incidence of acute pancreatitis is approximately two times higher in patients with type 2 diabetes. However, the authors did not find an increased risk for acute pancreatitis with exenatide or sitagliptin. The study has several limitations. Garg R, Chen W, Pendergrass M. Diabetes Care. 2010;33(11): Acute Pancreatitis The estimated risk for acute pancreatitis in the general population is events per 1000 adults per year 20% of cases are considered to be severe (hemorrhagic or necrotizing), with 2 4% resulting in death 1 2% of the cases are drug induced Forsmark CE, Baillie J. Gastroenterology. 2007;132(5): Whitcomb DC. N Engl J Med. 2006;354(20): Etiology of Pancreatitis 60 80% of pancreatitis cases are attributed to Alcohol Gallstones Severe hypertriglyceridemia 2.8-fold increased risk of acute pancreatitis in patients with diabetes (3-fold in men and 2.6-fold in women) 5-fold increased risk in the 18- to 44-year-old population with diabetes 1.9-fold risk of biliary disease was reported in patients with diabetes (cholelithiasis is the basis in 50% of the cases) Noel RA, Patterson RE, Braun DK, Bloomgren GL. Diabetes Care. 2009;32(5):

3 Drug-Induced Pancreatitis Of the top 100 prescribed drugs in the United States, 44 have been associated with acute pancreatitis These include acetaminophen, erythromycin, trimethoprim/sulfamethoxazole, agents used to treat human immunodeficiency virus, and oncologic agents No clear pathophysiologic basis connects the various agents Among diabetes medications, glyburide may be associated with an increased risk for pancreatitis, especially in patients with high BMI Trivedi CD, Pitchumoni CS. J Clin Gastroenterol. 2005;39(8): Blomgren KB, Steineck G, Sundstrom A, Wiholm BE. Diabetes Care. 2002;25(2): Incretins and Acute Pancreatitis In the exenatide development program: Six cases in 3489 subject-years of exenatide exposure (1.7/1000 subject-years) One case in 336 subject-years in placebo (3.0/1000 subjectyears) One case in 497 subject-years (2.0/1000 subject-years) for the insulin comparator Over 1 year, in 27,996 patients on exenatide and 16,276 on sitagliptin, the incidence of acute pancreatitis: 0.13% of exenatide users [RR 1.0; confidence interval (CI) )] 0.12% sitagliptin users [RR 1.0; CI )] Between 2006 and 2010, 88 cases of pancreatitis were reported in relation to sitagliptin (2 cases hemorrhagic or necrotizing) Amylin-Eli-Lilly report to the FDA. Dore DD, Seeger JD, Arnold Chan K. Curr Med Res Opin. 2009;25(4): Possible Etiology That Links Incretins to Acute Pancreatitis A few animal studies have shown incretin mimetic drugs to cause exocrine pancreatic duct hyperplasia that may eventually lead to acute or chronic pancreatitis or pancreatic carcinoma Matveyenko AV et al. Diabetes. 2009;58: Nachnani JS et al. Diabetologia. 2010;53:

4 Acute Pancreatitis: Crude Incidence Rates from Time-on-Drug Analysis Acute Pancreatitis Crude Incidence Rates per 100,000 Person-Years among Exenatide Initiators and Other Antidiabetic Drug* Initiators Incidence Rate/ 100,000 PY Exenatide N = 25,719 Other Antidiabetic Drugs* 218 *Includes initiators of N = 234,536 metformin, thiazolidinediones, Current Use Exenatide vs Other Recent Use Adjusted Rate Ratio Past Use 95% CI insulins, sulfonylureas, nonsulfonylurea secretagogues, Antidiabetic sitagliptin, pramlintide, Drugs and α-glucosidase Current Use Recent Use inhibitors; CI, confidence interval; PY, patient-years Past Use Bloomgren et al. Presented at ADA, 69th Scientific Sessions; 2009; New Orleans, LA (158-OR). Acute Pancreatitis Crude Incidence Rate from the Intent-to-Treat Analysis Acute Pancreatitis Crude Incidence Rate per 100,000 Person-Years among Exenatide Initiators and Other Antidiabetic Drug* Initiators Incidence Rates per 100,000 PY Intent-to-Treat 273 Exenatide vs Other Antidiabetic Drug Initiators 228 Adjusted 95% CI Rate Ratio Exenatide initiators N = 25,719 Other antidiabetic drug* initiators N = 234,536 *Includes initiators of metformin, thiazolidinediones, insulins, sulfonylureas, nonsulfonylurea secretagogues, sitagliptin, pramlintide, and α-glucosidase inhibitors; CI, confidence interval; PY, patient-years Bloomgren et al. Presented at ADA, 69th Scientific Sessions; 2009; New Orleans, LA (158-OR). Back to the Article Method: A retrospective cohort of a large medical and pharmacy claims database Data for 786,656 patients were analyzed Cox proportional hazard models were built to compare the risk of acute pancreatitis between: Subjects with and without diabetes Exenatide, sitagliptin, and control diabetes medication Garg R, Chen W, Pendergrass M. Diabetes Care. 2010;33(11):

5 Kaplan-Meier Curve of Acute Pancreatitis in Combined Groups (Exenatide, Sitagliptin, Diabetes Control) with Diabetes and the Control Group without Diabetes Garg R et al. Diabetes Care. 2010;33: Copyright 2011 American Diabetes Association, Inc. Kaplan-Meier Curve of Acute Pancreatitis in Exenatide, Sitagliptin, and Diabetes Control Groups Garg R et al. Diabetes Care. 2010;33: Copyright 2011 American Diabetes Association, Inc. Study Limitations Retrospective nature of the study Patients on exenatide or sitagliptin might be selected from low-risk patients (exclusion of who is likely to develop pancreatitis) Dataset did not provide clinical details such as type and duration of diabetes, obesity, glycemic and lipid control, alcohol consumption, or history of pancreatitis Providers may have used the acute pancreatitis code when evaluating patients for rule-out pancreatitis The possibility of asymptomatic chronic pancreatitis and the potential for pancreatic carcinoma were not investigated in this study 5

6 Back to Our Patient 43-year-old obese woman Long-standing type 2 diabetes Currently treated with metformin 1000 mg BID and glyburide 10 mg BID History of dyslipidemia treated with atorvastatin 40 mg/day and fenofibrate 120 mg/day History of silent solitary gall stone discovered incidentally by ultrasound for fatty liver Rarely drinks alcohol A1C 7.8% Back to Our Patient No history of pancreatitis Heard from a friend, who also has diabetes, that exenatide is a drug that may help her in controlling her diabetes and may also help her to lose weight She is asking for your opinion about adding exenatide to her current medications but she is concerned about the pancreatitis risk Should You Add Exenatide? In general, this patient is at high risk for pancreatitis: Obese Type 2 diabetes Hypertriglyceridemia (as shown from her fenofibrate treatment) Gall stones Increased risk in her age category 6

7 What Studies Would Help Clarify the Situation? Animal studies in type 2 diabetes model randomized to either incretin mimetic or placebo Prospective randomized controlled study without selection bias Discussion Points with Patient The association between incretin therapies and acute pancreatitis is weak, based on the available retrospective data Limitations of current studies Regardless of diabetes medications, the patient is at increased risk for acute pancreatitis Exenatide may help in controlling her diabetes and may also help her to lose weight It is likely that incretin therapy may increase the risk of pancreatitis in her situation She may need to check her fasting triglycerides Other options to control her diabetes without the risk of pancreatitis may be considered, such as adding longacting insulin Summary Pancreatitis is common among patients with diabetes. The risk for pancreatitis is increased when a patient has gall stones, hypertriglyceridemia, or is drinking alcohol. Drug-induced pancreatitis accounts for 1 2% of the pancreatitis cases. GLP-1 analogs, DPP-4 inhibitors, and another 44 medications are linked to pancreatitis, but there is no pathophysiologic link between them. In a large retrospective observational study, the relative risk for pancreatitis in relation to exenatide and sitaglipitin was 1.0, indicating a weak relationship A prospective randomized clinical trial with no selection bias is needed to confirm or decline the relationship between GLP-1 analogs, DPP-4 inhibitors, and acute pancreatitis 7

A retrospective observational pharmacy claims analysis

A retrospective observational pharmacy claims analysis Epidemiology/Health Services Research O R I G I N A L A R T I C L E Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin A retrospective observational pharmacy claims analysis RAJESH

More information

Type 2 Diabetes and Cancer: Is there a link?

Type 2 Diabetes and Cancer: Is there a link? Type 2 Diabetes and Cancer: Is there a link? Sonali Thosani, MD Assistant Professor Department of Endocrine Neoplasia & Hormonal Disorders MD Anderson Cancer Center No relevant financial disclosures Objectives

More information

ORIGINAL ARTICLE ASSESSMENT OF RISK OF ACUTE PANCREATITIS IN TYPE 2 DIABETES AND RISK REDUCTION ON ANTI- DIABETIC DRUGS: A COHORT STUDY

ORIGINAL ARTICLE ASSESSMENT OF RISK OF ACUTE PANCREATITIS IN TYPE 2 DIABETES AND RISK REDUCTION ON ANTI- DIABETIC DRUGS: A COHORT STUDY ORIGINAL ARTICLE ASSESSMENT OF RISK OF ACUTE PANCREATITIS IN TYPE 2 DIABETES AND RISK REDUCTION ON ANTI- DIABETIC DRUGS: A COHORT STUDY Shawana Barkat 1, Anil Sinha 2 1 Senior Resident, 2 Professor, Department

More information

Gastroenterology Attn.: Editor-in-Chief Anil K. Rustgi University of Pennsylvania Philadelphia

Gastroenterology Attn.: Editor-in-Chief Anil K. Rustgi University of Pennsylvania Philadelphia Gastroenterology Attn.: Editor-in-Chief Anil K. Rustgi University of Pennsylvania Philadelphia gastro@gastro.org, anil2@mail.med.upenn.edu Potentially damaging controversial analysis to be published in

More information

Diabetes update - Diagnosis and Treatment

Diabetes update - Diagnosis and Treatment Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes

More information

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold

More information

ORIGINAL INVESTIGATION. Glucagonlike Peptide 1 Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

ORIGINAL INVESTIGATION. Glucagonlike Peptide 1 Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus ORIGINAL INVESTIGATION Glucagonlike Peptide 1 Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study Sonal Singh, MD,

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study Diabetes Care Volume 38, June 2015 1089 Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study Reimar Wernich Thomsen, 1 Lars Pedersen, 1 Niels Møller,

More information

New Measure Recommended for Endorsement by PQA

New Measure Recommended for Endorsement by PQA New Measure Recommended for Endorsement by PQA Measure: Statin Use in Persons with Diabetes Description: The percentage of patients ages 40 75 years who were dispensed a medication for diabetes that receive

More information

Chief of Endocrinology East Orange General Hospital

Chief of Endocrinology East Orange General Hospital Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage

More information

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes

More information

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study Diabetes Care Publish Ahead of Print, published online September 10, 2010 Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study Short title: Diabetes,

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness

More information

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends + Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest

More information

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study Pawaskar et al. BMC Endocrine Disorders 2013, 13:20 RESEARCH ARTICLE Open Access Medication utilization patterns among type 2 diabetes patients initiating or insulin glargine: a retrospective database

More information

DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim

DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim Endocrinology of Metabolism, Korea University College of Medicine Conflict of interest disclosure None

More information

DR. SUBHASH K. WANGNOO

DR. SUBHASH K. WANGNOO Photograph DR. SUBHASH K. WANGNOO M.D, D.M, FRCP (London) Senior Consultant, Endocrinologist & Diabetologist Apollo Centre for Obesity, Diabetes and Endocrinology Indraprastha Apollo Hospital, Sarita Vihar,

More information

Early treatment for patients with Type 2 Diabetes

Early treatment for patients with Type 2 Diabetes Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona

More information

Non-insulin treatment in Type 1 DM Sang Yong Kim

Non-insulin treatment in Type 1 DM Sang Yong Kim Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay

More information

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,

More information

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1

More information

MOA: Long acting glucagon-like peptide 1 receptor agonist

MOA: Long acting glucagon-like peptide 1 receptor agonist Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication

More information

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes CLINICAL TRIAL Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes Nobuya Inagaki 1, Kohjiro Ueki 2, Ayuko Yamamura 3, Hitoshi Saito

More information

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes

More information

Learning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm

Learning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for

More information

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes

Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department

More information

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality

More information

Newer Drugs in the Management of Type 2 Diabetes Mellitus

Newer Drugs in the Management of Type 2 Diabetes Mellitus Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis

More information

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have

More information

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009

More information

Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy

Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens

More information

Thiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis

Thiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Thiazolidinediones and the risk of bladder cancer: A cohort study R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Study objective To investigate the risk of bladder cancer associated

More information

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013

IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013 IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications

More information

Wayne Gravois, MD August 6, 2017

Wayne Gravois, MD August 6, 2017 Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion

More information

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide

More information

Changing Diabetes: The time is now!

Changing Diabetes: The time is now! Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison

More information

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

CURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.

CURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S. CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3

More information

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical

More information

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the

More information

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing

More information

Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas

Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support

More information

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011

More information

Presented By: Creative Educational Concepts, Inc. Lexington, KY

Presented By: Creative Educational Concepts, Inc. Lexington, KY Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the

More information

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they

More information

Le incretine: un passo avanti. Francesco Dotta

Le incretine: un passo avanti. Francesco Dotta Le incretine: un passo avanti Francesco Dotta U.O.C. Diabetologia, Policlinico Le Scotte Università di Siena Fondazione Umberto Di Mario ONLUS Toscana Life Science Park Incretins: multiple targets multiple

More information

CURRENT CONTROVERSIES IN DIABETES CARE

CURRENT CONTROVERSIES IN DIABETES CARE CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and

More information

Joslin Diabetes Center Management of Diabetes in 2013: The Need to Combine Art and Science Weight Management in the Patient With Diabetes

Joslin Diabetes Center Management of Diabetes in 2013: The Need to Combine Art and Science Weight Management in the Patient With Diabetes Long-term Weight Management in Patients With Diabetes: The Why WAIT Model Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program Director of Inpatient Diabetes Management Joslin Diabetes

More information

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007 Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited

More information

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral

More information

Update on Diabetes Cardiovascular Outcome Trials

Update on Diabetes Cardiovascular Outcome Trials Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine

More information

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

DM Fundamentals Class 4 Meds for Type 2

DM Fundamentals Class 4 Meds for Type 2 DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds

More information

Approaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster

Approaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis

Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical

More information

Management of Type 2 Diabetes

Management of Type 2 Diabetes Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity

More information

Hong Qiu ALL RIGHTS RESERVED

Hong Qiu ALL RIGHTS RESERVED 2011 Hong Qiu ALL RIGHTS RESERVED ANTI-DIABETIC TREATMENT AND CANCER OCCURRENCE AMONG PATIENTS WITH TYPE II DIABETES MELLITUS By HONG QIU A dissertation submitted to the School of Public Health University

More information

CASE A2 Managing Between-meal Hypoglycemia

CASE A2 Managing Between-meal Hypoglycemia Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),

More information

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia

More information

It is estimated that approximately 20.8 million Americans

It is estimated that approximately 20.8 million Americans FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite

More information

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including

More information

Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680

Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680 Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680 Webappendix 7: Correspondence between the BMJ and the manufacturers or marketers of sitagliptin,

More information

OBESITY IN TYPE 2 DIABETES

OBESITY IN TYPE 2 DIABETES OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

Update on Diabetes Mellitus

Update on Diabetes Mellitus Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies

More information

Barriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia. KM Pantalone Endocrinology

Barriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia. KM Pantalone Endocrinology Barriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia KM Pantalone Endocrinology Disclosures Speaker Bureau AstraZeneca, Merck, Novo Nordisk, Sanofi Consultant Novo Nordisk, Eli Lilly, Merck

More information

Drug Class Monograph

Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),

More information

What s New in Diabetes Treatment. Disclosures

What s New in Diabetes Treatment. Disclosures What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None

More information

Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion

Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion Om P. Ganda, MD; Kirit Tolia, MD, FACE Postcardiac Follow-up in a 66-Year-Old Man Slide 1. Dr. Ganda: Now we will present a case

More information

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Multiple Factors Should Be Considered When Setting a Glycemic Goal Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent

More information

Sitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist

Sitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of

More information

Treatment of Type 2 Diabetes: What Have We Learned? AACE Diabetes Algorithm. ADOPT Trial 6/13/2012

Treatment of Type 2 Diabetes: What Have We Learned? AACE Diabetes Algorithm. ADOPT Trial 6/13/2012 Treatment of Type 2 Diabetes: What Have We Learned? Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering needed, patientspecific

More information

Diabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy

Diabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism

More information

Endo 2 SLO Practice (online) Page 1 of 7

Endo 2 SLO Practice (online) Page 1 of 7 Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined

More information

CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS. Mugdha Gokhale.

CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS. Mugdha Gokhale. CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS Mugdha Gokhale A dissertation submitted to the faculty at the University of North Carolina

More information

Diabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP

Diabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP Diabetes Update: Diabetes Management In Primary Care Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Critically evaluate the evidence emerging within diabetes research as it applies to recommendations

More information

Diabetes It s not just sugar

Diabetes It s not just sugar HeartWise 2014 April 11, 2014 Matthew A. Sauder, MD LG Health Physicians Diabetes and Endocrinology Diabetes It s not just sugar Objectives Review the link between diabetes and cardiovascular disease Discuss

More information

Type 2 Diabetes Mellitus 2011

Type 2 Diabetes Mellitus 2011 2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose

More information

What s New on the Horizon: Diabetes Medication Update

What s New on the Horizon: Diabetes Medication Update What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:

More information

GLP-1 Agonists Therapy in Individuals with Type 2 Diabetes Mellitus: A Review of Safety and Tolerability

GLP-1 Agonists Therapy in Individuals with Type 2 Diabetes Mellitus: A Review of Safety and Tolerability GLP-1 Agonists Therapy in Individuals with Type 2 Diabetes Mellitus: A Review of Safety and Tolerability Reprinted with permission of the authors and the Indiana Pharmacists Alliance where this article

More information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Timely!Insulinization In!Type!2! Diabetes,!When!and!How Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for

More information

DM Fundamentals Class 4 Meds for Type 2

DM Fundamentals Class 4 Meds for Type 2 DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds

More information

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

Diabetes Treatment Update

Diabetes Treatment Update Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers

More information

Treating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric

Treating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme

More information

Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?

Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM

More information

New Drug Evaluation: Dulaglutide

New Drug Evaluation: Dulaglutide Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information